Medicine pricing policies: Lessons from Vietnam

Southern Med Review

Volumn 3, Issue 2, 2010, Pages 12-19

  Nguyen, Anh Tuan ^a,b   Knight, Rosemary ^a   Mant, Andrea ^a   Cao, Quang Minh ^c   Brooks, Geoffrey ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

^c National Institute of Hygiene and Epidemiology   (Viet Nam)

^d Geoffrey Brooks and Associates Pty Ltd   (Australia)

Author keywords

Access to medicines; Medicine pricing policy; Policy cycle; Policy implementation; Vietnam

Indexed keywords

COST CONTROL; DRUG COST; DRUG MARKETING; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; INFORMATION DISSEMINATION; PHARMACEUTICAL CARE; PUBLICATION; REVIEW; SOCIOECONOMICS; VIET NAM;

EID: 78049253009     PISSN: None     EISSN: 11742704     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Rietveld AH, Haaijer Ruskamp FM (2002). Chapter 3: Policy options for cost containment of pharmaceuticals. In: Dukes MNG, Haaijer Ruskamp FM, De Joncheere CP, Rietveld AH, editors. Drugs and money - Prices, affordability and cost containment. 7th ed: IOS Press: 29-54.
2. Mrazek M, Mossialos E (2004). Chapter six: Regulating pharmaceutical prices in the European Union. In: Mossialos E, Mrazek M, Walley T, editors. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Maidenhead, England: Open University Press: 114-29.
3. Critchley W (2006), Report of ISTC mission on drug price controls in Vietnam. Hanoi: Vietnam Sweden Health Cooperation Project.
4. Kees de Joncheere, et al. (2002). Chapter 1: Scope of the problem. In: Dukes MNG, Haaijer Ruskamp FM, de Joncheere CP, Rietveld AH, editors. Drug and Money - Prices, affordability and cost containment. 7th ed: IOS Press: 7-13.
5. Witter S (1996), 'Doi Moi' and health: the effect of economic reforms on the health system in Vietnam. International Journal of Health Planning and Management,11:159-72.
6. Simonet D (2001), Une analyse du marché pharmaceutique vietnamien Cahiers d'études et de recherches francophones / Santé,11(3):155- 60.
7. The Council of Ministers. Decision of the Council of Ministers No104/HDBT of 30 June 1987 on retail prices of curative medicines. Hanoi1987.
8. Ministry of Health of Vietnam. Circular No 16/BYT-TT of 7 July 1987 on guiding the implementation of Decision of the Council of Ministers No 104 -HDBT of 30 June 1987 on retail prices of curative medicines. Hanoi1987.
9. Larsson M (2003), Antibiotic use and resistance, Assessing and improving utilisation and provision of antibiotics and other drugs in Vietnam. Stockholm, Sweden: Sciences Karolinska Institutet.
10. Chalker J (1995), Vietnam: profit and loss in health care. World Health Forum,16:194-5.
11. Nguyen AT, et al. (2009), Medicine prices, availability, and affordability in Vietnam. Southern Med Review,2(2):2-9.
12. The Inspectorate of the Ministry of Health. The inspection report No 317 of 2 May 2007.
13. SGGP. Import - pharmaceutical business: Superprofit 20 Jul 2007 http://www.sggp.org.vn/daututaichinh/2007/7/111378/ (Accussed16 Jun 2009)
14. Rist R (1994). Influencing the policy process with qualitative research. In: Denzin N, Lincoln Y, editors. Handbook of Qualitative Research. London, England: Sage Publications: 545-57.
15. Law No 17/2008/QH12: issuing regulatory documents of June 06, 2008, (2008).
16. Government Office of Vietnam. Informing document of the Government Office No 41/TB-VPCP of 28 March 2003 on the opinion of Deputy Prime Minister Nguyen Tan Dung about the problem of medicine price increases. 2003.
17. Government Office of Vietnam. Informing document of the Government Office No 166/TB-VPCP of 01 October 2003 on the opinion of Deputy Prime Minister Pham Gia Khiem about the management of prices of curative medicines for human. 2003.
18. Le H. The pharmaceutical market is unstable because of medicine price posting 24 September 2003 http://vietnamnet.vn/suckhoe/2003/9/30129/ (Accussed 14 June 2008)
19. Mossialos E, Mrazek MF (2002). Chapter 2: Data needed for developing and monitoring policies. In: Dukes MNG, Haaijer Ruskamp FM, De Joncheere CP, Rietveld AH, editors. Drugs and money - Prices, affordability and cost containment. 7th ed: IOS Press: 15-27. (Pubitemid 36398724)
20. Dickson M, Redwood H (1998), Pharmaceutical reference prices. How do they work in practice? Pharmacoeconomics,14(5):471-9.
21. McLaughin P (1997), Reference-based pricing of prescription drug. Canadian Journal of Cardiology,13(1):31-2.
22. Ioannides-Demos L, et al. (2002), Reference - based pricing schemes: effect on pharmaceutical expenditure, resource uitilisation and health outcomes. Pharmacoeconomics,20(9):577-91.
23. Knowledge Ecology International. PhRMA's asks regarding special 301, drug pricing and reimbursement 19 May 2010 http://keionline.org/node/805 (19 May.2010)
24. OECD. Pharmaceutical pricing policies in a global market 14 May 2009 http://www.centad.org/seminar/2.%20Price%20regulation/ OECD%20Pharma%20pricing%20policies.pdf (Accussed14 May 2009)
25. Cao QM (2008), Pharmaceutical Industry Development, Supply Demand Balancing Solutions to Stabilize the Vietnam Pharmaceutical Market. Hanoi: Ministry of Health.
26. Aaserud M, et al. (2006), Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews,(2).